BE2014C017I2 - - Google Patents

Info

Publication number
BE2014C017I2
BE2014C017I2 BE2014C017C BE2014C017C BE2014C017I2 BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2 BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 C BE2014C017 C BE 2014C017C BE 2014C017 I2 BE2014C017 I2 BE 2014C017I2
Authority
BE
Belgium
Application number
BE2014C017C
Other languages
French (fr)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15924444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BE2014C017I2 publication Critical patent/BE2014C017I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2014C017C 1999-06-17 2014-03-04 BE2014C017I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17150999 1999-06-17

Publications (1)

Publication Number Publication Date
BE2014C017I2 true BE2014C017I2 (en) 2019-05-21

Family

ID=15924444

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C017C BE2014C017I2 (en) 1999-06-17 2014-03-04

Country Status (26)

Country Link
US (11) US6462058B1 (en)
EP (3) EP1129088B1 (en)
KR (3) KR100407847B1 (en)
CN (1) CN1150186C (en)
AR (5) AR031069A1 (en)
AT (1) ATE391126T1 (en)
AU (1) AU778820B2 (en)
BE (1) BE2014C017I2 (en)
BR (1) BRPI0011674B8 (en)
CA (1) CA2375201C (en)
CY (2) CY1110384T1 (en)
DE (1) DE60038481T2 (en)
DK (2) DK1129088T3 (en)
ES (2) ES2426985T3 (en)
HU (1) HU229067B1 (en)
IL (2) IL145996A0 (en)
MX (1) MXPA01012642A (en)
MY (1) MY125399A (en)
NO (1) NO321168B1 (en)
NZ (1) NZ515702A (en)
PL (1) PL201068B1 (en)
PT (2) PT1129088E (en)
SI (1) SI1129088T1 (en)
TW (2) TWI289557B (en)
WO (2) WO2000078745A2 (en)
ZA (1) ZA200108331B (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
CN1193024C (en) 2000-04-28 2005-03-16 武田药品工业株式会社 Process for producing optically active sulfoxide derivatives
EP1293507B1 (en) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
KR20100002278A (en) 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 Crystal of (r)- or (s)-lansoprazole
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
KR100467100B1 (en) * 2002-03-20 2005-01-24 일양약품주식회사 A process for preparation of injection containing 2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl-5-(1H-pyrrol-1-yl)-1H-benzimidazole or Na salt thereof
AU2003224779A1 (en) * 2002-03-27 2003-10-13 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004085424A1 (en) 2003-03-24 2004-10-07 Eisai Co., Ltd. Process for production of sulfoxide derivatives or salts thereof in the amorphous state
US20070101907A1 (en) * 2003-06-20 2007-05-10 Ch Chemical (Pty) Ltd. Liner
JP2006528181A (en) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (en) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド Pharmaceutical preparations and treatment of digestive diseases caused by acids
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (en) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド Combination of proton pump inhibitor, buffer and non-steroidal anti-inflammatory drug
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP1790647B1 (en) 2004-09-13 2013-05-08 Takeda Pharmaceutical Company Limited Method for producing oxidized compound
EP2275088B2 (en) 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Method for producing granules
ES2259269B1 (en) 2005-03-03 2007-11-01 Esteve Quimica, S.A. PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE.
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
WO2007074909A1 (en) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Controlled release solid preparation
KR100758600B1 (en) * 2006-01-05 2007-09-13 주식회사 대웅제약 Method for preparing lansoprazole crystalline form A
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008068767A2 (en) * 2006-12-07 2008-06-12 Hetero Drugs Limited A novel crystalline form of lansoprazole
JP5366558B2 (en) 2006-12-28 2013-12-11 武田薬品工業株式会社 Orally disintegrating solid preparation
CN102014638A (en) * 2007-10-12 2011-04-13 武田制药北美公司 Method of treating gastrointestinal disorders independent of food intake
EP2222663A1 (en) * 2007-12-18 2010-09-01 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
EP2573082A1 (en) * 2007-12-31 2013-03-27 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
AU2009224247B2 (en) * 2008-03-10 2013-12-12 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
CA2717947C (en) * 2008-03-11 2020-07-07 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
CN101977909A (en) * 2008-03-18 2011-02-16 雷迪博士实验室有限公司 Dexlansoprazole process and polymorphs
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
BRPI0912478A2 (en) * 2008-05-14 2016-02-10 Watson Pharma Private Ltd r - (+) - lansoprazole alkylamine salt, process for preparing a stable r - (+) - lansoprazole alkylamine salt and pharmaceutical dosage form
WO2010013823A2 (en) * 2008-07-28 2010-02-04 Takeda Pharmaceutical Company Limited Pharmaceutical composition
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
IT1391758B1 (en) * 2008-11-11 2012-01-27 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF DEXLANSOPRAZOLO AMORFO
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (en) * 2008-11-18 2012-01-27 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF DEXLANSOPRAZOL
IT1392813B1 (en) 2009-02-06 2012-03-23 Dipharma Francis Srl CRYSTALLINE FORMS OF DEXLANSOPRAZOLE
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (en) * 2009-07-29 2012-09-05 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF CRYSTALLINE DEXLANSOPRAZOLE
CN102740856B (en) 2009-11-12 2015-02-18 特罗菲克斯制药股份有限公司 Crystal forms of neurotrophin mimetic compounds and salts thereof
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN102108076B (en) * 2009-12-23 2014-07-23 江苏豪森医药集团有限公司 Method for preparing amorphous dexlansoprazole
WO2011092665A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
US9085556B2 (en) 2010-03-31 2015-07-21 Ranbaxy Laboraotories Limited Salts of dexlansoprazole and their preparation
CA2795110C (en) * 2010-03-31 2015-06-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
EP2384747A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Oral Tablet Compositions Of Dexlansoprazole
EP2384745A3 (en) 2010-05-05 2012-01-18 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of dexlansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012074110A1 (en) 2010-12-03 2012-06-07 武田薬品工業株式会社 Orally disintegrating tablet
US20130273157A1 (en) 2010-12-27 2013-10-17 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
WO2012095859A1 (en) * 2011-01-12 2012-07-19 Hetero Research Foundation Polymorphs of dexlansoprazole salts
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
EP2723728A1 (en) * 2011-06-21 2014-04-30 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102875532B (en) * 2011-07-15 2015-05-13 上海睿智化学研究有限公司 (R)-lansoprazole isopropyl amine salt and crystal form and preparation method thereof
CN102875531B (en) * 2011-07-15 2015-08-19 上海睿智化学研究有限公司 A kind of (R)-lansoprazole anhydrous crystal forms and preparation method thereof
CN102875530A (en) * 2011-07-15 2013-01-16 上海睿智化学研究有限公司 (R)-lansoprazole tert-butylamine salt and crystal form and preparation method thereof
CN102234265B (en) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 Lansoprazole compound
CA2857457C (en) 2011-11-30 2018-05-01 Takeda Pharmaceutical Company Limited Dry coated tablet
KR20140113667A (en) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
CN103709139B (en) * 2012-10-09 2016-12-21 上海汇伦生命科技有限公司 The preparation method of anhydrous R-lansoprazole
CN104177333A (en) * 2013-05-24 2014-12-03 四川海思科制药有限公司 (R)-2-[[[3-methyl-4-(2,2,2-trifluoro ethoxy)-2-pyridyl) methyl] sulfinyl]-1 H-benzimidazole with stabile physical and chemical properties
CN104650035A (en) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 Dexlansoprazole hemihydrate compound
CN103664889B (en) * 2013-12-19 2014-11-19 悦康药业集团有限公司 Lansoprazole compound
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104844576B (en) * 2015-04-28 2017-03-08 山东罗欣药业集团股份有限公司 A kind of Lansoprazole or Dexlansoprazole crystal-form compound and preparation method thereof
CN104829594A (en) * 2015-05-15 2015-08-12 苗怡文 Pharmaceutical lansoprazole compound for treating gastric ulcer
CN105017218A (en) * 2015-07-01 2015-11-04 合肥安德生制药有限公司 R-lansoprazole crystal form and preparation method therefor
CN104958276A (en) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 Pharmaceutical lansoprazole composition capsule for treating gastric ulcer
CN104997738A (en) * 2015-08-10 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 Medicine lansoprazole compound dry suspension treating gastropathy
CN105399728B (en) * 2015-12-20 2017-11-28 寿光富康制药有限公司 A kind of processing method of R-lansoprazole suitable for industrialized production
CN108164507A (en) * 2016-12-07 2018-06-15 天津药物研究院有限公司 A kind of R-lansoprazole monocrystalline and its preparation method and application
TR201701461A2 (en) 2017-01-31 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric Coated Pharmaceutical Compositions of Dexlansoprazole
CN106866630B (en) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 A kind of preparation method of R-lansoprazole
CN107011329A (en) * 2017-05-05 2017-08-04 广州大光制药有限公司 Lansoprazole monohydrate crystal form and its crystallization preparation method
CN108794450B (en) * 2018-07-24 2022-08-19 浙江恒康药业股份有限公司 Method for preparing amorphous dexlansoprazole
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (en) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
DK171989B1 (en) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles
DE4035455A1 (en) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
SE504459C2 (en) 1994-07-15 1997-02-17 Astra Ab Process for the preparation of substituted sulfoxides
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
JP2001504462A (en) 1996-11-12 2001-04-03 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング (2,3-Dihydrobenzofuranyl) -thiazole as phosphodiesterase inhibitor
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (en) * 1996-11-22 1999-07-21 The Procter & Gamble Company Compositions containing bismuth and nsaid for the treatment of gastrointestinal diseases.
SE510666C2 (en) 1996-12-20 1999-06-14 Astra Ab New Crystal Modifications
AU742620B2 (en) 1998-01-30 2002-01-10 Sepracor, Inc. R-lansoprazole compositions and methods
AU2481899A (en) 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
EP1075267A2 (en) * 1998-05-06 2001-02-14 Kobenhavns Universitet Treatment of celiac disease
JP3283252B2 (en) * 1999-06-17 2002-05-20 武田薬品工業株式会社 Crystals of benzimidazole compounds
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
CN1117747C (en) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 Preparation method of optical purity lansoprazole
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
WO2004085424A1 (en) * 2003-03-24 2004-10-07 Eisai Co., Ltd. Process for production of sulfoxide derivatives or salts thereof in the amorphous state
EP1827429A4 (en) * 2004-12-20 2009-08-05 Reddys Lab Ltd Dr Pharmaceutical compositions comprising amorphous benzimidazole compounds
CN101111233A (en) * 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 Stable oral benzimidazole composition and preparation method thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
EP2222663A1 (en) * 2007-12-18 2010-09-01 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole

Also Published As

Publication number Publication date
US20110319450A1 (en) 2011-12-29
CA2375201A1 (en) 2000-12-28
US20150025115A1 (en) 2015-01-22
US7737282B2 (en) 2010-06-15
ES2426985T3 (en) 2013-10-28
PT1977751E (en) 2013-08-01
DK1129088T3 (en) 2008-06-09
CN1355798A (en) 2002-06-26
BR0011674A (en) 2002-03-19
SI1129088T1 (en) 2008-08-31
BRPI0011674B8 (en) 2021-05-25
DE60038481D1 (en) 2008-05-15
PT1129088E (en) 2008-05-05
NO321168B1 (en) 2006-03-27
NZ515702A (en) 2003-07-25
NO20016087L (en) 2001-12-13
US9145389B2 (en) 2015-09-29
US6939971B2 (en) 2005-09-06
KR100537029B1 (en) 2005-12-16
ATE391126T1 (en) 2008-04-15
US7339064B2 (en) 2008-03-04
KR100407847B1 (en) 2003-12-01
PL352193A1 (en) 2003-08-11
HK1038227A1 (en) 2002-03-08
EP1977751A1 (en) 2008-10-08
EP2343289A1 (en) 2011-07-13
US8884019B2 (en) 2014-11-11
AR093609A2 (en) 2015-06-10
EP1977751B1 (en) 2013-07-24
DE60038481T2 (en) 2009-04-09
WO2000078745A3 (en) 2001-07-05
DK1977751T3 (en) 2013-09-02
HK1123985A1 (en) 2009-07-03
KR20030068592A (en) 2003-08-21
US20040048898A1 (en) 2004-03-11
BRPI0011674B1 (en) 2017-05-30
TWI289557B (en) 2007-11-11
AR079473A2 (en) 2012-01-25
US6462058B1 (en) 2002-10-08
CN1150186C (en) 2004-05-19
PL201068B1 (en) 2009-03-31
US20090163553A1 (en) 2009-06-25
NO20016087D0 (en) 2001-12-13
US20140012006A1 (en) 2014-01-09
CY1114485T1 (en) 2017-01-25
US20100222391A1 (en) 2010-09-02
US6664276B2 (en) 2003-12-16
AR103295A2 (en) 2017-05-03
EP1129088A2 (en) 2001-09-05
AR100473A2 (en) 2016-10-12
CY1110384T1 (en) 2015-04-29
MY125399A (en) 2006-07-31
HUP0201659A2 (en) 2002-11-28
ES2300265T3 (en) 2008-06-16
US7569697B2 (en) 2009-08-04
US20080132547A1 (en) 2008-06-05
US8030333B2 (en) 2011-10-04
WO2000078745A2 (en) 2000-12-28
US8552198B2 (en) 2013-10-08
HU229067B1 (en) 2013-07-29
TWI275587B (en) 2007-03-11
AU778820B2 (en) 2004-12-23
AR031069A1 (en) 2003-09-10
CA2375201C (en) 2010-02-09
IL145996A (en) 2008-07-08
ZA200108331B (en) 2002-10-10
KR100514204B1 (en) 2005-09-13
AU5247800A (en) 2001-01-09
MXPA01012642A (en) 2002-07-22
KR20010052467A (en) 2001-06-25
US20050228026A1 (en) 2005-10-13
US20030045724A1 (en) 2003-03-06
HUP0201659A3 (en) 2003-11-28
US20120316344A1 (en) 2012-12-13
EP1129088B1 (en) 2008-04-02
IL145996A0 (en) 2002-07-25
KR20010071354A (en) 2001-07-28
WO2004083200A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
BE2018C020I2 (en)
BE2015C057I2 (en)
BE2016C007I2 (en)
BE2015C018I2 (en)
BE2013C020I2 (en)
BE2013C015I2 (en)
BE2013C001I2 (en)
BE2012C036I2 (en)
JP2002509768A5 (en)
BE1025464I2 (en)
JP2002513255A5 (en)
JP2002517853A5 (en)
BRPI0017527B8 (en)
JP2002510150A5 (en)
BE2008C047I2 (en)
BE2011C004I2 (en)
BRPI0001672A2 (en)
JP2002524298A5 (en)
JP2002514478A5 (en)
JP2002522942A5 (en)
BRPI0001542A2 (en)
JP2002515585A5 (en)
JP2002502929A5 (en)
JP2002520787A5 (en)
BRPI0012675B8 (en)